Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

Fig. 4

Time to onset of action (≥10 % improvement from baseline FEV1) on Day 1 (mITT population). Cumulative data are shown. Adjusted difference versus placebo: *p < 0.05; **p < 0.01; ***p < 0.001; ****p ≤ 0.0001. Adjusted difference versus open-label tiotropium: † p < 0.05; †† p < 0.01; ††† p < 0.001; †††† p ≤ 0.0001. Time to onset was defined as the first post-baseline time when a ≥10 % improvement in FEV1 was seen relative to baseline FEV1, where baseline was defined as the mean of evaluable 60- and 30-min pre-dose values across Visits 2, 5, 8, and 11. P-values were obtained using the Murray method to account for correlation between the times to onset observed in the same subject at different periods. FEV 1 forced expiratory volume in 1 s; GP glycopyrrolate; MDI metered dose inhaler; mITT modified intent-to-treat

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us